Johnson & Johnson will spin off its $9.2B orthopedics business into a new company, DePuy Synthes, to focus on faster-growing medtech areas.

The planned separation is the latest move by J&J to slim down in recent years and focus on faster-growing businesses.

Johnson & Johnson (NYSE: JNJ) announced today that it intends to separate its DePuy Synthes Orthopaedics business.

Johnson & Johnson reported third-quarter sales of $24 billion, beating the FactSet consensus estimate of $23.8 billion.

Beyond the banks, we hear from Johnson & Johnson, which should have the strongest numbers of any pharmaceutical company.

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced it has completed its acquisition of Shockwave Medical. Shockwave is now part of Johnson & Johnson and will operate ...

Johnson & Johnson said on Tuesday it plans to separate its orthopedics business into a standalone company within the next 18 ...

Johnson & Johnson’s stock rose toward a record after a beat-and-raise earnings report and announcement of plans to separate ...

Another year, another multibillion-dollar cardiovascular acquisition for Johnson & Johnson MedTech. The company has inked a $13.1 billion deal to bring Shockwave Medical into the fold. J&J MedTech ...

Johnson & Johnson announced Friday it will buy medical device maker Shockwave Medical for nearly $13.1 billion in a move the company hopes will help it further combat heart disease. Founded in 1886, J ...

Johnson & Johnson said Tuesday it will buy heart failure implant company V-Wave in a deal worth a potential $1.7 billion. J&J entered into a definitive agreement to acquire the privately held company ...

It looks like Johnson & Johnson will have to part with nearly a billion dollars. A Los Angeles jury ordered Johnson & Johnson ...